Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022) - Hong, D.; Shergill, A.; Bazhenova, L.; Cho, B.C.; Heist, R.; Moreno, V.; Falchook, G.S.; Nagasaka, M.; Cassier, P.; Besse, B.; Kim, D.W.; Yoon, S.; et al.